Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Lenalidomide in High-risk MDS and AML with del(5q)
NCT01556477Phase 2Unknown
- Sponsor
- Nordic MDS Group
- Start
- Mar 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Nordic MDS Group. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01556477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556477.